New hope for tough lung cancers: ivonescimab combo enters phase 3 trial
NCT ID NCT06928389
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial is testing whether adding the experimental drug ivonescimab to standard chemotherapy (docetaxel) helps people with advanced non-small cell lung cancer live longer. The study includes 536 adults whose cancer worsened after prior immunotherapy. Participants are randomly assigned to receive either ivonescimab or a placebo, both combined with docetaxel. The main goal is to see if the combination improves overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ivonescimab and docetaxel
What this could lead to
If it works, this could offer a new treatment option for people with advanced lung cancer whose disease has worsened after standard immunotherapy.
What could go wrong
This is still an experimental combination; it may not improve survival or could cause more side effects than the current standard. Results are not yet known.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL-CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai East Hospital
RECRUITINGShanghai, Shanghai Municipality, China
Contact